HK Stock Market Move | BOAN BIOTECH(06955) rose nearly 4% as BA1203 (masked PD-1/IL-2) received clinical trial approval, intended for development in the treatment of multiple solid tumors.

BOAN BIOTECH(06955) rose nearly 4%, up 3.75% as of press time, at HK$2.625, with a turnover of HK$2.2693 million. On the news front, on September 14, BOAN BIOTECH announced that the Investigational New Drug (IND) application for its in-development PD-1/IL-2 antibody cytokine prodrug BA1203 has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration, and is intended for development in the treatment of multiple solid tumors. To the company's knowledge, this investigational drug is the world's only IL-2 receptor high-activity, masked, and PD-1-blocking PD-1/IL-2 molecule. BA1203, as the company's independently developed next-generation IO drug candidate, combines the dual mechanism of action of a PD-1 antibody and an IL-2 cytokine, aiming to simultaneously achieve immune checkpoint blockade and localized tumor immune activation. Following this approval to enter clinical trials, the company plans to conduct a multicenter, open-label Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of BA1203 in patients with advanced solid tumors, to further validate its advantages in efficacy and safety, and to explore its development path as a monotherapy and in combination therapy, fully unlocking BA1203's differentiated therapeutic potential in PD-1 target binding, immune pathway blockade, and tumor microenvironment immune activation.